Skip to main content

Archives

Blog

Video: Transitioning from paediatric to adult IBD

Posted: April 26 2021

Watch video here. Transcript: Stephen Hanauer, MD: Welcome to this HCPLive® Peers and Perspectives® presentation entitled, “Expert Perspectives on the Optimal Management of Inflammatory Bowel Disease.” I’m Dr Stephen Hanauer, from Northwestern University in Chicago, and I’m delighted to be joined by Dr Marla Dubinsky, from the Icahn School of Medicine at Mount Sinai in New […]

Read more

Research

Greenspace exposure during childhood reduces risk for IBD

Childhood exposure to residential greenspace was associated with a reduced risk for inflammatory bowel disease, according to data published in the American Journal of Gastroenterology.

By Monica Stonehill “Intervention studies designed to target specific environmental risk factors to reduce the risk of IBD should include greenspace in study design,” Michael Elten, MSc, from the School of Epidemiology and Public Health, University of Ottawa in Canada, and colleagues wrote. “It is possible that by changing our immediate environment, we could prevent childhood-onset IBD.” Elten and colleagues […]

Read more

News

New potential therapy for Crohn’s disease in children

Posted: February 24 2021

Scientists from the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago demonstrated that a nanotherapy reduces intestinal inflammation and shrinks lesions in a rodent model of severe Crohn’s disease. This approach could become an alternative to biologic antibody therapies that carry many side effects, including increased risk of certain cancers. […]

Read more

News

First-line treatment with infliximab versus conventional treatment

Posted: January 31 2021

Abstract Objective In newly diagnosed paediatric patients with moderate-to-severe Crohn’s disease (CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and immunomodulator therapies have failed. We aimed to investigate whether starting first-line IFX (FL-IFX) is more effective to achieve and maintain remission than conventional treatment. Design In this multicentre open-label randomised controlled trial, untreated patients […]

Read more

News

Gut research identifies key cellular changes associated with childhood-onset Crohn’s Disease

Posted: December 14 2020

The results are an important step towards better management and treatment of this devastating condition.  The research from the University of Cambridge and the Wellcome Sanger Institute is part of the global Human Cell Atlas initiative to map every cell type in the human body. The findings reveal intricate cellular mechanisms of how the gut […]

Read more

News

Cure found for rare form of inflammatory bowel disease

Posted: October 18 2020

The disease, called G6PC3 deficiency, affects around one in a million people and causes inflammation of the bowel, as well as lung infections. The team also showed that in affected patients, white blood cells called neutrophils trigger inflammation when exposed to gut bacteria, despite treatment with commonly available biological therapies. The patients were treated at the Royal […]

Read more